toripalimab
junshi biosciences,coherus
['neotorch', 'toripalimab']
 neotorch peri-operative toripalimab (anti-pd1)&amp; chemo 82.2% proceed to surgery
efs hr 0.4
mpr 48.5%
pcr 24.8% more evidence for pre-op chemo-io with similar levels of patients proceeding to surgery / pcr
#asco2023 
Thoracic Medical Oncologist @BartsHospital, PhD in genomic medicine @Imperialcollege, Representative @ACPUK & @BTOGorg, @FMLM_UK clinical Fellow ‘18